S-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Tyliew
01-26

S

康哲药业将联手麦济生物共同推动MG-K10人源化单抗注射液于中国市场上市

发稿人张敏本报讯（记者李雯珊）1月24日，康哲药业控股有限公司（以下简称“康哲药业”）发布公告称，通过其附属公司与湖南麦济生物技术股份有限公司（“麦济生物”）及其附属公司就1类新药抗IL-4Rα人源化单抗注射液MG-K10签订合作协议。根据协议，康哲药业获得MG-K10在中国及新加坡的共同开发权及独家商业化权利。

康哲药业将联手麦济生物共同推动MG-K10人源化单抗注射液于中国市场上市

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":396805470794304,"tweetId":"396805470794304","gmtCreate":1737901270731,"gmtModify":1737901273895,"author":{"id":3586350955637820,"idStr":"3586350955637820","authorId":3586350955637820,"authorIdStr":"3586350955637820","name":"Tyliew","avatar":"https://static.tigerbbs.com/160e574cf1b0ade27622b7fde3d21d2b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>S</p></body></html>","htmlText":"<html><head></head><body><p>S</p></body></html>","text":"S","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/396805470794304","repostId":2506359631,"repostType":2,"repost":{"id":"2506359631","kind":"news","pubTimestamp":1737891399,"share":"https://www.laohu8.com/m/news/2506359631?lang=&edition=full","pubTime":"2025-01-26 19:36","market":"us","language":"zh","title":"康哲药业将联手麦济生物共同推动MG-K10人源化单抗注射液于中国市场上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2506359631","media":"证券日报","summary":"发稿人张敏本报讯（记者李雯珊）1月24日，康哲药业控股有限公司（以下简称“康哲药业”）发布公告称，通过其附属公司与湖南麦济生物技术股份有限公司（“麦济生物”）及其附属公司就1类新药抗IL-4Rα人源化单抗注射液MG-K10签订合作协议。根据协议，康哲药业获得MG-K10在中国及新加坡的共同开发权及独家商业化权利。","content":"<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.00867&amp;imageType=k&amp;token=28dfeb41d35cc81d84b4664d7c23c49f&amp;at=1\" width=\"578\"/></p><p>　　发稿人张敏</p><p>　　本报讯 （记者李雯珊）1月24日，<span><a href=\"https://laohu8.com/S/00867\">康哲药业</a></span>控股有限公司（以下简称“<span href=\"http://quote.eastmoney.com/unify/r/116.00867\" target=\"_blank\" web=\"1\">康哲药业</span>”）发布公告称，通过其附属公司与湖南麦济生物技术股份有限公司（“麦济生物”）及其附属公司就1类新药抗IL-4Rα人源化单抗注射液MG-K10签订合作协议。</p><p>　　根据协议，<span href=\"http://quote.eastmoney.com/unify/r/116.00867\" target=\"_blank\" web=\"1\">康哲药业</span>获得MG-K10在中国及新加坡的共同开发权及独家商业化权利。据悉，MG-K10是一种创新的长效抗IL-4Rα人源化单抗，主要用于治疗包括特应性皮炎、哮喘等多种2型炎症性疾病。</p><p>　　目前MG-K10的特应性皮炎（AD）、哮喘和结节性痒疹已进入中国的III期临床试验阶段，且在成人中重度AD和哮喘的II期临床试验中显示出良好的疗效和安全性。</p><p>　　据弗若斯特沙利文报告，中国IL-4Rα靶向疗法的市场规模预期将于2030年达到40.8亿美元，2020年至2030年的复合年增长率为76.8%。目前已上市的抗IL-4Rα药物均需要每2周给药一次，而MG-K10只需每4周给药一次，同时呈现良好的疗效和安全性，具有成为同类最优（BIC）的潜力。</p><p>　　康哲药业相关人士对外表示，MG-K10将丰富公司在皮肤疾病治疗领域的全球差异化创新管线，并与现有产品组合高度协同。此外，公司将与麦济生物全力推动MG-K10于中国市场上市，为中国2型炎症性疾病相关患者带来给药频次更低，兼具良好疗效及安全性的治疗新选择。</p><p>（文章来源：<span>证券</span><span></span>日报）</p> </div></body></html>","source":"stock_eastmoney","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲药业将联手麦济生物共同推动MG-K10人源化单抗注射液于中国市场上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲药业将联手麦济生物共同推动MG-K10人源化单抗注射液于中国市场上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-26 19:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202501263308459833.html><strong>证券日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>发稿人张敏　　本报讯 （记者李雯珊）1月24日，康哲药业控股有限公司（以下简称“康哲药业”）发布公告称，通过其附属公司与湖南麦济生物技术股份有限公司（“麦济生物”）及其附属公司就1类新药抗IL-4Rα人源化单抗注射液MG-K10签订合作协议。　　根据协议，康哲药业获得MG-K10在中国及新加坡的共同开发权及独家商业化权利。据悉，MG-K10是一种创新的长效抗IL-4Rα人源化单抗，主要用于治疗包括...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202501263308459833.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"YINN":"三倍做多富时中国ETF-Direxion","00867":"康哲药业","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","MG":"Mistras Group","BK1191":"制药","BK1593":"医美概念股","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","BK4585":"ETF&股票定投概念","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","SG9999015978.USD":"利安颠覆性创新基金A","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","BK4588":"碎股","BK4123":"调查和咨询服务"},"source_url":"http://finance.eastmoney.com/a/202501263308459833.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2506359631","content_text":"发稿人张敏　　本报讯 （记者李雯珊）1月24日，康哲药业控股有限公司（以下简称“康哲药业”）发布公告称，通过其附属公司与湖南麦济生物技术股份有限公司（“麦济生物”）及其附属公司就1类新药抗IL-4Rα人源化单抗注射液MG-K10签订合作协议。　　根据协议，康哲药业获得MG-K10在中国及新加坡的共同开发权及独家商业化权利。据悉，MG-K10是一种创新的长效抗IL-4Rα人源化单抗，主要用于治疗包括特应性皮炎、哮喘等多种2型炎症性疾病。　　目前MG-K10的特应性皮炎（AD）、哮喘和结节性痒疹已进入中国的III期临床试验阶段，且在成人中重度AD和哮喘的II期临床试验中显示出良好的疗效和安全性。　　据弗若斯特沙利文报告，中国IL-4Rα靶向疗法的市场规模预期将于2030年达到40.8亿美元，2020年至2030年的复合年增长率为76.8%。目前已上市的抗IL-4Rα药物均需要每2周给药一次，而MG-K10只需每4周给药一次，同时呈现良好的疗效和安全性，具有成为同类最优（BIC）的潜力。　　康哲药业相关人士对外表示，MG-K10将丰富公司在皮肤疾病治疗领域的全球差异化创新管线，并与现有产品组合高度协同。此外，公司将与麦济生物全力推动MG-K10于中国市场上市，为中国2型炎症性疾病相关患者带来给药频次更低，兼具良好疗效及安全性的治疗新选择。（文章来源：证券日报）","news_type":1},"isVote":1,"tweetType":1,"viewCount":27,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}